Reviva Pharmaceuticals announces $10M public offering of stock and warrants

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Offering of 6,666,667 shares (or pre-funded warrants) plus Series G and H warrants at $1.50/unit; gross proceeds $10M.
Series G warrants exercisable at $1.50 for 5 years; Series H warrants exercisable at $1.50 for 1 year.
Net proceeds ~$9M to fund RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and for working capital.
Closing expected March 20, 2026; A.G.P./Alliance Global Partners acting as sole placement agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the aggregate gross proceeds (effective 2026-03-18).

Action: entry
Agreement: underwriting
Counterparty: A.G.P./Alliance Global Partners
Value: 7.0% of the aggregate gross proceeds
Effective: 2026-03-18

Exact text from the filing

the Company entered into a placement agency agreement (the “Placement Agency Agreement”), dated March 18, 2026, with A.G.P./Alliance Global Partners (the “Placement Agent”) pursuant to which the Company agreed to pay the Placement Agent a total cash fee equal to 7.0% of the aggregate gross proceeds of the Offering

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Purchase Agreement with certain institutional investors valued at $10.0 million (effective 2026-03-18).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: $10.0 million
Effective: 2026-03-18

Exact text from the filing

On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into agreements, including a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) an aggregate of 6,283,334 shares (the “Shares”) of the Company’s common stock

View on SEC.gov

Browse all material agreements →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-009063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.